Over the past decade, numerous studies have investigated the potential anti-cancer properties of metformin. Epidemiological data have suggested that patients with diabetes who are on metformin have a lower incidence of certain types of cancer compared to those on other anti-diabetic drugs. This has spurred interest in its potential role as an adjuvant therapy in cancer treatment.
